Incyte
American pharmaceutical company
From Wikipedia, the free encyclopedia
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware.[2] The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.[3]
| |
| Company type | Public |
|---|---|
| Industry | pharmaceuticals |
| Founded | 2002 |
| Founder | Roy A. Whitfield |
| Headquarters | Wilmington, Delaware, U.S. |
Key people | Bill Meury (CEO & president) |
| Revenue |  US$4.24 billion (2024) |
 US$61.4 million (2024) | |
| US$32.6 million (2024) | |
| Total assets | US$5.44 billion (2024) |
| Total equity | US$3.45 billion (2024) |
Number of employees | 2,617 (2024) |
| Website | incyte |
| Footnotes / references [1] | |
Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.
History
In June 2025, Incyte named Bill Meury president, CEO, and a member of the board of directors. He replaced Hervé Hoppenot, who retired after 11 years of service.[4]
In September 2015, the company announced it had gained exclusive development and commercial right pertaining to Jiangsu Hengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal worth $795+ million.[5]
In January 2020, Incyte signed a collaboration and license agreement for the global development and commercialization of tafasitamab with MorphoSys.[6] On March 3, 2020, the agreement received antitrust clearance and thus became effective.[7]
Incyte established a European headquarters in Morges, Switzerland, in 2021.[8]
Pharmaceuticals
Incyte Corporation currently has seven marketed and co-marketed pharmaceutical products, including Jakafi (ruxolitinib), Pemazyre (pemigatinib), Monjuvi (tafasitamab-cxix), Opzelura (Ruxolitinib), Tabrecta (capmatinib), Olumiant (Baricitinib), and Iclusig (ponatinib).[9] [10] In 2013, Novartis acquired Incyte's c-Met inhibitor capmatinib (INC280, INCB028060), which is marketed under the brand name Tabrecta.[11]
As of 2014, the company was developing baricitinib, an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly.[12][13] It gained EU approval in February 2017.[14] In April 2017, the US FDA issued a rejection, citing concerns about dosing and safety.[15][16] In May 2018, baricitinib was approved in the United States for the treatment of rheumatoid arthritis under the brand name Olumiant.[17][18]
As of 2016 epacadostat, an indoleamine 2,3-dioxygenase (IDO1) inhibitor, was in development for various cancers and was in combination trials with Merck's pembrolizumab (Keytruda) and Bristol Myers Squibb's nivolumab (Opdivo).[19][20]
Acquisition history
Incyte has made a total of 3 acquisitions.
- Maxia Pharmaceuticals (2003): An early acquisition in Incyte's history, the company purchased Maxia in 2003 for $42 million. [21]
- Villaris Therapeutics (2022): This acquisition was valued at approximately $1.4 billion and included an upfront payment along with milestones. It added new assets to Incyte's portfolio for treating vitiligo and other autoimmune conditions. [22]
- Escient Pharmaceuticals (2024): In May 2024, Incyte acquired this San Diego-based, clinical-stage company for $750 million. The acquisition provided Incyte with two oral drug candidates for inflammatory diseases, EP262 and EP547.[23]